Suppr超能文献

阻塞性肺疾病气道重塑消退的新靶点。

New targets for resolution of airway remodeling in obstructive lung diseases.

作者信息

Nayak Ajay P, Deshpande Deepak A, Penn Raymond B

机构信息

Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, USA.

出版信息

F1000Res. 2018 May 30;7. doi: 10.12688/f1000research.14581.1. eCollection 2018.

Abstract

Airway remodeling (AR) is a progressive pathological feature of the obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The pathology manifests itself in the form of significant, progressive, and (to date) seemingly irreversible changes to distinct respiratory structural compartments. Consequently, AR correlates with disease severity and the gradual decline in pulmonary function associated with asthma and COPD. Although current asthma/COPD drugs manage airway contraction and inflammation, none of these effectively prevent or reverse features of AR. In this review, we provide a brief overview of the features and putative mechanisms affecting AR. We further discuss recently proposed strategies with promise for deterring or treating AR.

摘要

气道重塑(AR)是阻塞性肺疾病(包括哮喘和慢性阻塞性肺疾病(COPD))的一种进行性病理特征。其病理表现为不同呼吸结构腔室出现显著、进行性且(迄今为止)似乎不可逆的变化。因此,AR与疾病严重程度以及哮喘和COPD相关的肺功能逐渐下降有关。尽管目前的哮喘/COPD药物可控制气道收缩和炎症,但这些药物均无法有效预防或逆转AR的特征。在本综述中,我们简要概述了影响AR的特征和假定机制。我们还进一步讨论了最近提出的有望阻止或治疗AR的策略。

相似文献

1
New targets for resolution of airway remodeling in obstructive lung diseases.
F1000Res. 2018 May 30;7. doi: 10.12688/f1000research.14581.1. eCollection 2018.
2
Progress in the development of kinase inhibitors for treating asthma and COPD.
Adv Pharmacol. 2023;98:145-178. doi: 10.1016/bs.apha.2023.04.004. Epub 2023 May 3.
3
Mechanisms of airway remodeling.
Chest. 2013 Sep;144(3):1026-1032. doi: 10.1378/chest.12-3073.
4
Remodeling in asthma and COPD--differences and similarities.
Clin Respir J. 2010 May;4 Suppl 1:20-7. doi: 10.1111/j.1752-699X.2010.00193.x.
5
Bitter Taste Receptors for Asthma Therapeutics.
Front Physiol. 2019 Jul 16;10:884. doi: 10.3389/fphys.2019.00884. eCollection 2019.
6
Differences in airway remodeling between asthma and chronic obstructive pulmonary disease.
Clin Rev Allergy Immunol. 2004 Aug;27(1):35-43. doi: 10.1385/CRIAI:27:1:035.
7
Airway Remodeling in Asthma: Mechanisms, Diagnosis, Treatment, and Future Directions.
Arch Bronconeumol. 2025 Jan;61(1):31-40. doi: 10.1016/j.arbres.2024.09.007. Epub 2024 Sep 24.
8
Remodeling in asthma and chronic obstructive lung disease.
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 2):S28-38. doi: 10.1164/ajrccm.164.supplement_2.2106061.
9
[The effects of NOX4 and TGF-βinvolved in airway remodeling of Chronic Obstructive Pulmonary Disease].
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2017 Jun 8;33(6):481-487. doi: 10.12047/j.cjap.5601.2017.115.
10
Are chronic obstructive pulmonary disease (COPD) and asthma different diseases?
Clin Exp Allergy. 1998 Nov;28 Suppl 5:187-94; discussion 203-5. doi: 10.1046/j.1365-2222.1998.028s5187.x.

引用本文的文献

1
Drugs Used in the Treatment of Viral Infections for the Prevention of Airway Remodeling in Asthma.
Mediators Inflamm. 2025 Jul 24;2025:5526526. doi: 10.1155/mi/5526526. eCollection 2025.
4
A-Kinase-Anchoring Protein Subtypes Differentially Regulate GPCR Signaling and Function in Human Airway Smooth Muscle.
Am J Respir Cell Mol Biol. 2025 Feb;72(2):133-144. doi: 10.1165/rcmb.2023-0358OC.
5
Diacylglycerol kinase is a keystone regulator of signaling relevant to the pathophysiology of asthma.
Am J Physiol Lung Cell Mol Physiol. 2024 Jul 1;327(1):L3-L18. doi: 10.1152/ajplung.00091.2024. Epub 2024 May 14.
6
Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression.
Can Respir J. 2023 Nov 29;2023:3291957. doi: 10.1155/2023/3291957. eCollection 2023.
10
Selective Inhibition of Extracellular Signal-regulated Kinases 1 and 2: When Less Is More.
Am J Respir Cell Mol Biol. 2023 Jan;68(1):1-2. doi: 10.1165/rcmb.2022-0376ED.

本文引用的文献

2
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
MAbs. 2018 Jan;10(1):34-45. doi: 10.1080/19420862.2017.1392425. Epub 2017 Nov 14.
3
Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model.
Exp Lung Res. 2017 May-Jun;43(4-5):187-196. doi: 10.1080/01902148.2017.1339141. Epub 2017 Jul 11.
4
Bitter taste receptor agonists alter mitochondrial function and induce autophagy in airway smooth muscle cells.
Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L154-L165. doi: 10.1152/ajplung.00106.2017. Epub 2017 Apr 27.
5
Bitter Taste Receptor Agonists Mitigate Features of Allergic Asthma in Mice.
Sci Rep. 2017 Apr 11;7:46166. doi: 10.1038/srep46166.
6
Mitochondrial Dysfunction in Airway Disease.
Chest. 2017 Sep;152(3):618-626. doi: 10.1016/j.chest.2017.03.020. Epub 2017 Mar 21.
8
Mitogen-activated protein kinases as therapeutic targets for asthma.
Pharmacol Ther. 2017 Jun;174:112-126. doi: 10.1016/j.pharmthera.2017.02.024. Epub 2017 Feb 14.
10
Heterogeneity of airway wall dimensions in humans: a critical determinant of lung function in asthmatics and nonasthmatics.
Am J Physiol Lung Cell Mol Physiol. 2017 Mar 1;312(3):L425-L431. doi: 10.1152/ajplung.00421.2016. Epub 2017 Jan 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验